Terkko Navigator / Molecular Oncology

Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4‐driven transcriptional state

Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions

The transcribed ultraconserved region uc.160+ enhances processing and A‐to‐I editing of the miR‐376 cluster: hypermethylation improves glioma prognosis

PD‐1‐induced T cell exhaustion is controlled by a Drp1‐dependent mechanism

USP35 mitigates endoplasmic‐reticulum‐stress‐induced apoptosis by stabilizing RRBP1 in non‐small cell lung cancer

Malignant‐ascites‐derived small extracellular vesicles in advanced ovarian cancer patients: insights into the dynamics of the extracellular matrix

UBE2T promotesβ‐catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK‐dependent activation

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study

Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer

Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST5) in pituitary and pancreatic neuroendocrine tumors

Corrigendum to: Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA

Sortilin‐related receptor is a druggable therapeutic target in breast cancer

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)

Human intestinal and circulating invariant Natural Killer T cells are cytotoxic against colorectal cancer cells via the perforin–granzyme pathway

PD‐1‐induced T cell exhaustion is controlled by a Drp1‐dependent mechanism

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations

Elesclomol induces copper‐dependent ferroptosis in colorectal cancer cells via degradation of ATP7A

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations

The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor

Chemoradiotherapy‐induced increase in Th17 cell frequency in cervical cancer patients is associated with therapy resistance and early relapse

The Porto European Cancer Research Summit 2021

Viruses in colorectal cancer

The Porto European Cancer Research Summit 2021

Viruses in colorectal cancer

Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial

hnRNP‐A1 binds to the IRES of MELOE‐1 antigen to promote its translation in stressed melanoma cells

Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC

Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study

A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer

ERK signaling controls productive HIF‐1 binding to chromatin and cancer cell adaptation to hypoxia through HIF‐1α interaction with NPM1

STAT3 is required for Smo‐dependent signaling and mediates Smo‐targeted treatment resistance and tumorigenesis in Shh medulloblastoma

Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy

STAT3 is required for Smo‐dependent signaling and mediates Smo‐targeted treatment resistance and tumorigenesis in Shh medulloblastoma

Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small cell lung cancer treated with pembrolizumab

Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion

Multi‐omic molecular profiling guides efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial

Blood DNA methylation profiles improve breast cancer prediction

A novel anti‐c‐Kit antibody–drug conjugate to treat wild‐type and activating‐mutant c‐Kit‐positive tumors

Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor

EWS–FLI1‐targeting peptide identifies Ewing sarcoma tumor boundaries and lymph node metastasis via near‐infrared imaging

Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells

Elesclomol induces copper‐dependent ferroptosis in colorectal cancer cells via degradation of ATP7A

ERK signalling controls productive HIF‐1 binding to chromatin and cancer cell adaptation to hypoxia through HIF‐1α interaction with NPM1